Neomorphic mutations create therapeutic challenges in cancer

V. Takiar, C. K.M. Ip, M. Gao, Gordon Mills, L. W.T. Cheung

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Oncogenesis is a pathologic process driven by genomic aberrations, including changes in nucleotide sequences. The majority of these mutational events fall into two broad categories: inactivation of tumor suppressor genes (hypomorph, antimorph or amorph) or activation of oncogenes (hypermorph). The recent surge in genome sequence data and functional genomics research has ushered in the discovery of aberrations in a third category: gain-of-novel-function mutation (neomorph). These neomorphic mutations, which can be found in both tumor suppressor genes and oncogenes, produce proteins with entirely different functions from their respective wild-type (WT) proteins and the other morphs. The unanticipated phenotypic outcomes elicited by neomorphic mutations imply that tumors with the neomorphic mutations may not respond to therapies designed to target the WT protein. Therefore, understanding the functional activities of each genomic aberration to be targeted is crucial in devising effective treatment strategies that will benefit specific cancer patients.

Original languageEnglish (US)
Pages (from-to)1607-1618
Number of pages12
JournalOncogene
Volume36
Issue number12
DOIs
StatePublished - Mar 23 2017
Externally publishedYes

Fingerprint

Mutation
Tumor Suppressor Genes
Neoplasms
Oncogene Proteins
Pathologic Processes
Therapeutics
Genomics
Oncogenes
Carcinogenesis
Proteins
Genome
Research

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Takiar, V., Ip, C. K. M., Gao, M., Mills, G., & Cheung, L. W. T. (2017). Neomorphic mutations create therapeutic challenges in cancer. Oncogene, 36(12), 1607-1618. https://doi.org/10.1038/onc.2016.312

Neomorphic mutations create therapeutic challenges in cancer. / Takiar, V.; Ip, C. K.M.; Gao, M.; Mills, Gordon; Cheung, L. W.T.

In: Oncogene, Vol. 36, No. 12, 23.03.2017, p. 1607-1618.

Research output: Contribution to journalReview article

Takiar, V, Ip, CKM, Gao, M, Mills, G & Cheung, LWT 2017, 'Neomorphic mutations create therapeutic challenges in cancer', Oncogene, vol. 36, no. 12, pp. 1607-1618. https://doi.org/10.1038/onc.2016.312
Takiar, V. ; Ip, C. K.M. ; Gao, M. ; Mills, Gordon ; Cheung, L. W.T. / Neomorphic mutations create therapeutic challenges in cancer. In: Oncogene. 2017 ; Vol. 36, No. 12. pp. 1607-1618.
@article{b7e50cdd0ee34fe1b4c600a33d10a892,
title = "Neomorphic mutations create therapeutic challenges in cancer",
abstract = "Oncogenesis is a pathologic process driven by genomic aberrations, including changes in nucleotide sequences. The majority of these mutational events fall into two broad categories: inactivation of tumor suppressor genes (hypomorph, antimorph or amorph) or activation of oncogenes (hypermorph). The recent surge in genome sequence data and functional genomics research has ushered in the discovery of aberrations in a third category: gain-of-novel-function mutation (neomorph). These neomorphic mutations, which can be found in both tumor suppressor genes and oncogenes, produce proteins with entirely different functions from their respective wild-type (WT) proteins and the other morphs. The unanticipated phenotypic outcomes elicited by neomorphic mutations imply that tumors with the neomorphic mutations may not respond to therapies designed to target the WT protein. Therefore, understanding the functional activities of each genomic aberration to be targeted is crucial in devising effective treatment strategies that will benefit specific cancer patients.",
author = "V. Takiar and Ip, {C. K.M.} and M. Gao and Gordon Mills and Cheung, {L. W.T.}",
year = "2017",
month = "3",
day = "23",
doi = "10.1038/onc.2016.312",
language = "English (US)",
volume = "36",
pages = "1607--1618",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Neomorphic mutations create therapeutic challenges in cancer

AU - Takiar, V.

AU - Ip, C. K.M.

AU - Gao, M.

AU - Mills, Gordon

AU - Cheung, L. W.T.

PY - 2017/3/23

Y1 - 2017/3/23

N2 - Oncogenesis is a pathologic process driven by genomic aberrations, including changes in nucleotide sequences. The majority of these mutational events fall into two broad categories: inactivation of tumor suppressor genes (hypomorph, antimorph or amorph) or activation of oncogenes (hypermorph). The recent surge in genome sequence data and functional genomics research has ushered in the discovery of aberrations in a third category: gain-of-novel-function mutation (neomorph). These neomorphic mutations, which can be found in both tumor suppressor genes and oncogenes, produce proteins with entirely different functions from their respective wild-type (WT) proteins and the other morphs. The unanticipated phenotypic outcomes elicited by neomorphic mutations imply that tumors with the neomorphic mutations may not respond to therapies designed to target the WT protein. Therefore, understanding the functional activities of each genomic aberration to be targeted is crucial in devising effective treatment strategies that will benefit specific cancer patients.

AB - Oncogenesis is a pathologic process driven by genomic aberrations, including changes in nucleotide sequences. The majority of these mutational events fall into two broad categories: inactivation of tumor suppressor genes (hypomorph, antimorph or amorph) or activation of oncogenes (hypermorph). The recent surge in genome sequence data and functional genomics research has ushered in the discovery of aberrations in a third category: gain-of-novel-function mutation (neomorph). These neomorphic mutations, which can be found in both tumor suppressor genes and oncogenes, produce proteins with entirely different functions from their respective wild-type (WT) proteins and the other morphs. The unanticipated phenotypic outcomes elicited by neomorphic mutations imply that tumors with the neomorphic mutations may not respond to therapies designed to target the WT protein. Therefore, understanding the functional activities of each genomic aberration to be targeted is crucial in devising effective treatment strategies that will benefit specific cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84995476916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995476916&partnerID=8YFLogxK

U2 - 10.1038/onc.2016.312

DO - 10.1038/onc.2016.312

M3 - Review article

VL - 36

SP - 1607

EP - 1618

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 12

ER -